Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care

Posted on May 11, 2015 in Research

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.

The organizations will work on initiatives that bring together Boehringer Ingelheim’s research and development expertise in novel medications to address unmet therapeutic needs with Sutter Health’s research and clinical experience from caring for a diverse population of more than 3 million patients in its network of hospitals and healthcare providers.

The first collaborative initiative will focus on chronic obstructive pulmonary disease (COPD). Chronic lower respiratory diseases, which include COPD, rank third in leading causes of death in the United States. Healthcare providers have told approximately 15 million Americans that they have COPD. Through this initial project, the team hopes to make it easier for doctors and patients to work together to personalize medical care to the patient’s unique needs and preferences.

“Ultimately, we all want to help patients reduce COPD symptoms and live healthier lives,” said Walter ‘Buzz’ Stewart, Ph.D., MPH, chief research officer for Sutter Health. “We believe that innovative technologies can help us develop a deeper understanding of patient needs, values, and care preferences—and create more time during office visits for doctors and patients to partner toward improved health outcomes.”

Specifically, the initial collaboration between the two companies aims to achieve the following:

  • Develop a reliable, electronic (tablet or kiosk-based) data collection system to collect information directly from the patient, during every health encounter
  • Make it easier for healthcare professionals and patients to communicate about treatment options by developing technological means for integrating clinical and patient reported data in an engaging visual display
  • Empower shared decision making through the use of visual displays and other technologies that help connect patients and healthcare professionals and create more personal care

Read More

Sutter Health and AstraZeneca form Research Collaboration to Transform Care for Diabetes and other Cardiometabolic Conditions

Posted on May 5, 2015 in Research

AstraZeneca and not-for-profit Sutter Health today announced the start of a research and innovation collaboration. The organizations will team up over the next three years to design, prototype and pilot innovative approaches to improve the lives of cardiometabolic patients by creating a more personalized, health care experience through physician and patient partnership.

Cardiometabolic care focuses on the treatment and management of diseases such as diabetes, hypertension and high cholesterol and common, co-occurring serious health complications such as heart attack, stroke, limb loss, blindness and even death. Through this collaboration, researchers will explore how to re-engineer the delivery of cardiometabolic care by improving access to and understanding of electronic health record data, testing new care models and experimenting with leading-edge technologies. Read More

State of Sutter: A Look Back at 2014

Posted on Jan 20, 2015 in Community Benefit, Expanding Access, Quality, Research, Transformation

A look back at some of Sutter Health’s key milestones in 2014.

Quality Achievement – Our commitment to quality and service means patients receive the excellent medical care they deserve, leading to better treatment results and a better quality of life. Our network received numerous awards for health care quality in 2014.

  • 15 Top Health Systems Truven logo





Read More

$2 Million Awarded to Sutter Health, IBM and Geisinger Health System to Study Heart Failure Prediction

Posted on Oct 9, 2013 in Research

Three year collaboration will develop groundbreaking, big data analytic methods to improve care and reduce costs for treatment of heart disease

Sutter Health, IBM Research (NYSE: IBM) and Geisinger Health System announce the award of a $2 million joint research grant from the National Institutes of Health (NIH) to develop new and sophisticated big data analytics and application methods that could help doctors detect heart failure years sooner than is now possible.

Heart disease is the leading cause of death, disability and costly hospitalizations in the United States. One in five adults will develop heart failure, a type of heart disease that remains nearly impossible to detect early.  About half of people who have heart failure die within five years of diagnosis.

The Research Project

Sutter Health, IBM and Geisinger Health System will use the NIH funding to develop practical and cost-effective early-detection methods for application in primary care practices with an electronic health record (EHR) system. The research aims to:

CPMC Leads Study on Link Between Turmeric and BPA Exposure

Posted on Dec 17, 2012 in Research, Uncategorized

Study on Turmeric's Effects on BPA ExposureResearchers at Sutter Health affiliated California Pacific Medical Center Research Institute (CPMCRI) announced an exciting new research study which investigates the effects main ingredients of the spice turmeric have on bisphenol-A, or BPA, exposure.

Low doses of curcumin, a key ingredient in turmeric, was found to reverse many of the major changes caused by exposure to BPA. BPA exposure has long been linked as a potential risk factor for developing breast cancer and other developmental conditions, such as fetal abnormalities and possibly male cancers such as prostate cancer.

It’s said to be the first study of is kind offering promise that the effects of BPA can be reversed by main elements of the spice turmeric. Learn more on California Pacific Medical Center’s newsroom.

Sutter Neuroscience Institute Launches Groundbreaking Clinical Trial on Autism

Posted on Aug 21, 2012 in Research

In partnership with Cord Blood Registry, the the world’s largest stem cell bank, Sutter Neuroscience Institute started the first FDA-approved clinical trial to study the use of a child’s own newborn stems cells in treatment for patients with autism.

This first-of-its-kind medical research comes at at a time when autism is said to effect one in 88 children in the United States, and one in 54 boys, according to the Centers for Disease Control and Prevention. Although the condition is thought to have multiple risk factors, including genetic, environmental and immunological components, the study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior.

Read more on Sutter Medical Center, Sacramento’s newsroom.